EP0147443A1 - Pyrimidine derivatives - Google Patents

Pyrimidine derivatives

Info

Publication number
EP0147443A1
EP0147443A1 EP19840902351 EP84902351A EP0147443A1 EP 0147443 A1 EP0147443 A1 EP 0147443A1 EP 19840902351 EP19840902351 EP 19840902351 EP 84902351 A EP84902351 A EP 84902351A EP 0147443 A1 EP0147443 A1 EP 0147443A1
Authority
EP
European Patent Office
Prior art keywords
compound
azido
group
acid addition
addition salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19840902351
Other languages
German (de)
French (fr)
Inventor
Edward A. Bliss
Roger John Griffin
Malcolm Francis Graham Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aston Molecules Ltd
Wellcome Foundation Ltd
Original Assignee
Aston Molecules Ltd
University of Birmingham
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aston Molecules Ltd, University of Birmingham, Wellcome Foundation Ltd filed Critical Aston Molecules Ltd
Publication of EP0147443A1 publication Critical patent/EP0147443A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Definitions

  • the present invention relates to azido-substituted pyrixaidine derivatives. More specifically it concerns azido derivat ives of 2 ,4diamino-5-phenylpyrimidines , the preparat ion thereof , pharmaceutical formulations thereof and the use thereof in therapy.
  • the azido group may act as a "pseudohalide” group (see A. Treinin, in “The Chemist ry of the Azido Group” , Editor S . Patai; publisher John Wiley & Sons , 1971 , pp 1-55) and in its lipophilic and electronic characteristics bears affinities with halogen substituents which have found wide use as biologically acceptable groups in drug molecules . It has also been reported that aromat ic azides can act as pro-drug modif icat ions for the corresponding aromatic amines (E .A. Bliss , T .B . Brown, M.F.G. Stevens, and C.K. Wong , J. Pharm.
  • the present invention provides, in a first aspect, compounds of the general formula (I):
  • R 1 radical is selected from hydrogen, halogen, or alkoxy having a carbon chain of 1-4 carbon atoms, while R 2 is hydrogen or an alkyl group of 1-4 carbon atoms, and the invention further includes acid addition salts of compounds of the said general formula (I).
  • the azido group is in the 3'-position of the phenyl group
  • a said radical R 1 consisting of a chlorine, bromine or iodine atom or an alkoxy group of 1-4 carbon atoms is in the 4'-position of the phenyl group
  • the said radical R 2 is an alkyl group of 1-4 carbon atoms.
  • Particularly preferred compounds within this first class comprise azido-substituted pyrimidine derivatives of formulas (la - Id) below and acid addition salts thereof:
  • the azido group is in the 4'-posit ion of the phenyl group, a said radical R 1 consisting of a chlorine, bromine or iodine atom or an alkoxy group of
  • Particularly preferred compounds within this second class comprise azido-substituted pyrimidine derivatives of formulas (Ie - If) below and acid addition salts thereof :
  • Acid addition salts of compounds of formula (I) are preferably pharmaceutically acceptable although other acid addition salts are within the scope of the invention.
  • Suitable salts are those derived from, for example, the following acids : hydrochloric, hydrobromic, sulphuric, nitric, isethionic, phosphoric, maleic, salicylic, p-toluenesulphonic, tartaric , citric , lactobionic , formic , malonic , pantothenic , succinic , naphthalene-2-sulphonic, benzenesulphonic, methanesulphonic and ethanesulphonic.
  • the preferred salt s in terms of pharmaceutical acceptability are the ethanesulphonic acid salts.
  • the compounds of formula (I) may be prepared by adapting or using any method or synthetic procedure known ih the art for the preparation of compounds of analogous structure.
  • compounds of formula (I), at least wherein the azido group is in the 3'- or 4'- position of the phenyl group may be prepared by using either of the following procedures:
  • R 1 and R 2 are as hereinbefore defined, and Y is a residue or group such as alkoxy (e.g. methoxy, ethoxy), aralkoxy (e.g. benzyloxy), alkylthio (e.g. methylthio), aralkylthio (e.g. benzylthio) or a secondary or tertiary amino group (e.g. dimethylamino, diethyl amino, or other dialkylamino group; anilino; morpholino).
  • alkoxy e.g. methoxy, ethoxy
  • aralkoxy e.g. benzyloxy
  • alkylthio e.g. methylthio
  • aralkylthio e.g. benzylthio
  • a secondary or tertiary amino group e.g. dimethylamino, diethyl amino, or other dialkylamino group; anilino;
  • the compounds of the invention have been found to inhibit dihydrofolate reductase (DHFR) in mammals and other biological systems and to have antitumour activity; they also appear to have some antipsoriatic and antimalarial activity.
  • DHFR dihydrofolate reductase
  • Such antitumour activity is evidenced for example by reduction of tumour cell number in mammals bearing ascitic tumours and their consequent increase in survival as compared to a control group which is untreated.
  • Antitumour activity is further evidenced by measurable reduction in the size of solid tumours following treatment with the compounds of this invention compared to the tumours of untreated control animals.
  • the murine tumour lines against which the compounds of formula (I) are active include, but are not limited to, lymphocytic leukemia P388, lymphocytic leukemia L1210, melanotic melanoma B16 , Colon 38, TLX5 lymphoma, W3129 myeloma, Walker 256 and M5 recticulura cell sarcoma.
  • the compounds of the present invention are useful for the treatment of tumours.
  • the invention thus further provides a method for the treatment of tumours in animals, including mammals, which comprises the administration of an effective, non-toxic amount of the compound of formula (I), or an acid addition salt thereof, orally, parenterally (including subcutaneous, intramuscular and intravenous), or applied topically.
  • the administration will generally be carried out repetitively at intervals, for example once or several times a day.
  • a compound of formula (I) or an acid addition salt thereof for use in therapy for example as an antitumour agent.
  • the amount of compounds of formula (I) required to be effective as an antitumour agent for treating mammals will, of course, vary and is ultimately at the discretion of the medical or veterinary practitioner treating the mammal in each particular case.
  • the factors to be considered by such a practitioner, e.g. a physician, include the route of administration and pharmaceutical formulation; the mammal's body weight, surface area, age and general condition; and the particular salt or ester to be administered.
  • a suitable effective antitumour dose is in the range of about 1.0 to about 75mg/kg bodyweight, preferably in the range of about 5 to 40mg/kg with most suitable doses being for example in the range 10 to 30mg/kg.
  • the total daily dose may be given as a single dose, multiple doses, e.g. two to six times per day, or by intravenous infusion for any selected duration.
  • the dose range would be about 75 to 500mg per day, and a typical dose would cqmraonly be about 100mg per day.
  • treatment might typically be 50mg of a compound, of formula (I) given 4 times per day in the form of a tablet, capsule, liquid (e.g. syrup) or injection.
  • the antitumour activity of the compounds of formula (I) resides in the free base and thus the nature of the acid participating in the acid addition salts is of minor importance.
  • the salts of the compound of formula (I) should be both pharmacologically and pharmaceutically acceptable, but nonpharmaceutically and non-pharmacologically acceptable salts may conveniently be used to prepare the free active compound or pharmaceutically acceptable salts thereof and are not excluded from the scope of this Invention.
  • Formulations of the present invention comprise the active compound together with one or more pharmaceutically acceptable carriers thereof and, optionally, any other therapeutic ingredients.
  • the carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof .
  • the present invention therefore further provides a pharmaceutical formulation comprising a compound of formula (I) (in the form of the free base or a pharmaceutically acceptable acid addition salt) together with a pharmaceutically acceptable carrier therefor.
  • the formulations include those suitable for oral, rectal or parenteral (including subcutaneous, intramuscular and intravenous) administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include generally the step of bringing the active compound into association with a carrier which constitutes one or more accessory Ingredients. Usually, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier or with a finely divided solid carrier or with both and then, if necessary, shaping the product into desired formulations.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active compound; as a powder or granules; or a suspension In an aqueous liquid or non-aqueous liquid such as a syrup, an elixir, an emulsion or a draught.
  • the active compound may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the active compound in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, Inert diluent, surface active or dispersing agent.
  • Moulded tablets may be made by moulding, In a suitable machine, a mixture of the powdered active compound with any suitable carrier.
  • a syrup may be made by adding the active compound to a concentrated, aqueous solution of a sugar, for example sucrose, to which may be added any accessory ingredient.
  • a sugar for example sucrose
  • Such accessory ingredient(s) may include flavourings, an agent to retard crystallisation of the sugar or an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol for example glycerol or sorbitol.
  • Formulations for rectal administration may be presented as a suppository with a usual carrier such as cocoa butter.
  • Formulations suitable for parental administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably isotonic with the blood of the recipient.
  • the formulations of this Invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • accessory ingredient(s) selected from diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
  • 2,4-diamino-5-(3-nitro-4-chlorophenyl)-6-ethylpyrimidine 16g was added in small portions with stirring over 15 minutes to a solution of tin (II) chloride dihydrate (38g) in 10N-hydro- chloric acid (160ml) that was maintained at 5-10°C. The mixture was stirred thoroughly for 1.5 hours (using a mortar) and allowed to stand overnight. The white stannicomplex that was produced was collected, dissolved in hot water and basified to pH 14 with 10N sodium hydroxide.
  • a sample of the crude white precipitate was also crystallised from 50% aqueous ethanol to afford colourless needles of the amine monohydrate, m.p. 215-217°C, m/e 265(31%), 263(96%; M + ) , 247(100%);
  • the ethanesulphonate salt was prepared as follows: the azide (3.0g) was suspended in water (20ml) and ethanesulphonic acid (1.2g) was added. The mixture was heated to boiling and the solid dissolved. On cooling the salt crystallised out and was collected; it was then recrystallised from water to afford cream microcrystals (2.2g), m.p. 202-203°C (with decomposition); v 3350, 3175, 2900 (NH,) and max
  • the crude aminopyrimidine (1.84g) was converted to 2, 4-diamino-5-(4-azido-3-chlorophenyl)-6-ethy Ipyrimidine by dissolving in 5N-hydrochloric acid (60 ml) at 0°C and treating the mixture, successively with sodium nitrite (0.6g) followed by sodium azide (1.8g) in the manner described for the synthesis of compound (la).
  • the ethanesulphonate salt was prepared from the azide base and ethanesulphonic acid and crystallised from water as cream crystals, m.p. 196-197°C (decomp.) Found : C, 42.2; H, -4.4; N, 24.2%
  • This azidopyrimidine was prepared from 2,4-diamino-5-(4-amino-3chlorophenyl)-6-methylpyrimidine (m.p. 242-244oC) by the diazotisation and azidation procedure described in detail for the synthesis of compound (la).
  • the ethanesulphonate salt was prepared from the azide base and ethanesulphonic acid in the manner described previously and crystallised from water as cream crystals, m.p. 202-203°C; ⁇ max 2140 (N 3 ) cm -1 .
  • This azidopyrimidine was likewise prepared from 2 ,4-diamino-5(3-amino-4-ethoxyphenyl)-6-ethylpyrimidine (m.p. 176-177 °C) by t reatment with sodium nitrite and sodium azide using the procedure used successfully for the synthesis of compound ( la ) .
  • the azide base was converted to the ethanesulphonate salt by treatment with ethanesulphonic acid in the manner previous ly described .
  • the cream salt crystallised from water as microcrystals , m.p. 173-174 °C ( decomp .) ; ⁇ 2140 (N 3 ) cm -1 m ax Found C, 47.1; H, 5.8; N, 23.8%
  • CD2-F mice of the same sex, weighing within a 3 gram range surrounding 20g, are used for this test.
  • Control and test animals are injected intraperitoneally with a suspension of 10 6 viable P388/0 tumour cells on day 0.
  • each dose level group contains 6 animals.
  • the test compounds are prepared either in physiologic saline containing 0.05% Tween 80 or distilled water containing 5% dextrose and are administered intraperitoneally on days 1 to 9 relative to tumour implant. Doses are on a mg/kg basis according to individual animals' body weights.
  • the day of death for each animal is recorded, the median identified for each group and the ratios of median survival time for treated (T)/control (C) groups are calculated.
  • the criterion for activity is T/C x 100 120%.
  • the results are summarised in Table II balow. No toxicity was observed with 9 daily doses of up to 200 mg/kg and increases in survival time of up to 57% were observed.
  • mice Groups of 5 female BALB/C mice were inoculated s.c. with 5 x

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des 2,4-diamino-5-phénylepyrimidines sous la forme de la base libre ou d'un de leurs sels d'addition d'acide présentent la formule générale (I), où R1 est de l'hydrogène, un halogène ou un groupe alcoxy possédant une chaîne de carbone comportant de 1 à 4 atomes de carbone tandis que R2 est de l'hydrogène ou un groupe alkyle comportant de 1 à 4 atomes de carbone. Les composés sont utiles dans le traitement thérapeutique, par exemple en tant qu'agents antitumoraux, antipsoriatiques et antimalariens, et des préparations pharmaceutiques en permettant l'administration à des mammifères sont décrites. Des composés particulièrement utiles, notamment dans la thérapie antitumorale, possèdent le groupe azido en position 3' ou 4' et R1 en position 4' ou 3' du groupe phényle.2,4-diamino-5-phenylepyrimidines in the form of the free base or one of their acid addition salts have the general formula (I), where R1 is hydrogen, halogen or a alkoxy group having a carbon chain having from 1 to 4 carbon atoms while R2 is hydrogen or an alkyl group having from 1 to 4 carbon atoms. The compounds are useful in therapeutic treatment, for example as anti-tumor, anti-psoriatic and anti-malarial agents, and pharmaceutical preparations allowing administration to mammals are described. Particularly useful compounds, in particular in the antitumor therapy, have the azido group in position 3 'or 4' and R1 in position 4 'or 3' of the phenyl group.

Description

PYRIMIDINE DERIVATIVES
TECHNICAL FIELD
The present invention relates to azido-substituted pyrixaidine derivatives. More specifically it concerns azido derivat ives of 2 ,4diamino-5-phenylpyrimidines , the preparat ion thereof , pharmaceutical formulations thereof and the use thereof in therapy.
BACKGROUND ART
It is known that the azido group may act as a "pseudohalide" group (see A. Treinin, in "The Chemist ry of the Azido Group" , Editor S . Patai; publisher John Wiley & Sons , 1971 , pp 1-55) and in its lipophilic and electronic characteristics bears affinities with halogen substituents which have found wide use as biologically acceptable groups in drug molecules . It has also been reported that aromat ic azides can act as pro-drug modif icat ions for the corresponding aromatic amines (E .A. Bliss , T .B . Brown, M.F.G. Stevens, and C.K. Wong , J. Pharm. Pharmacol . , 1979 , 315 , 66P; E.A. Bliss , Ph.D Thesis , University of Aston in Birmingham, Birmingham, England , 1980) . It is also known that some aromatic azides can potentially degrade in vivo to short-lived reactive chemical intermediates in the manner in which they degrade thermally and photochemically ("The Chemistry of the Azido Group," Editor S . Patai, John Wiley & Sons , 1971 , pp. 221330 and pp. 441-502) and this property might perhaps suggest exploitation of the use of such aromat ic azides as radiosensitizing agents in the treatment of cancer or in photochemotherapy of overproliferative skin disorders ( skin cancer or psoriasis) .
However, so far as is known no aromatic azido compounds have ever been used therapeutically for treatment in connection with human or animal disease and no aromatic azido compounds known to be useful or effeective for this purpose have hitherto been available. DISCLOSURE OF THE INVENTION
The present invention provides, in a first aspect, compounds of the general formula (I):
wherein the or each R1 radical is selected from hydrogen, halogen, or alkoxy having a carbon chain of 1-4 carbon atoms, while R2 is hydrogen or an alkyl group of 1-4 carbon atoms, and the invention further includes acid addition salts of compounds of the said general formula (I).
In a first class of preferred compounds, the azido group is in the 3'-position of the phenyl group, a said radical R1 consisting of a chlorine, bromine or iodine atom or an alkoxy group of 1-4 carbon atoms is in the 4'-position of the phenyl group, and the said radical R2 is an alkyl group of 1-4 carbon atoms. Particularly preferred compounds within this first class comprise azido-substituted pyrimidine derivatives of formulas (la - Id) below and acid addition salts thereof:
H
In a second class of preferred compounds, the azido group is in the 4'-posit ion of the phenyl group, a said radical R1 consisting of a chlorine, bromine or iodine atom or an alkoxy group of
1-4 carbon atoms is in the 3 '-position of the phenyl group, and the said radical R2 is an alkyl group of 1-4 carbon atoms. Particularly preferred compounds within this second class comprise azido-substituted pyrimidine derivatives of formulas (Ie - If) below and acid addition salts thereof :
Acid addition salts of compounds of formula (I) [including compounds of formulas ( la - If) ] are preferably pharmaceutically acceptable although other acid addition salts are within the scope of the invention. Suitable salts are those derived from, for example, the following acids : hydrochloric, hydrobromic, sulphuric, nitric, isethionic, phosphoric, maleic, salicylic, p-toluenesulphonic, tartaric , citric , lactobionic , formic , malonic , pantothenic , succinic , naphthalene-2-sulphonic, benzenesulphonic, methanesulphonic and ethanesulphonic. The preferred salt s in terms of pharmaceutical acceptability are the ethanesulphonic acid salts. The compounds of formula (I) may be prepared by adapting or using any method or synthetic procedure known ih the art for the preparation of compounds of analogous structure. For example, compounds of formula (I), at least wherein the azido group is in the 3'- or 4'- position of the phenyl group, may be prepared by using either of the following procedures:
(1) Diazotisation of the corresponding amino compound, for example the 3'- or 4'-amino compound, of formula (II) below, wherein R1 and R2 are as hereinbefore defined in relation to the compounds of formula (I), followed by treatment with azide. The compounds of formula (II) may themselves be obtained by reduction of the corresponding nitro compounds.
(2) React ion with guanidine of an azido compound of formula (III) ,
wherein R1 and R2 are as hereinbefore defined, and Y is a residue or group such as alkoxy (e.g. methoxy, ethoxy), aralkoxy (e.g. benzyloxy), alkylthio (e.g. methylthio), aralkylthio (e.g. benzylthio) or a secondary or tertiary amino group (e.g. dimethylamino, diethyl amino, or other dialkylamino group; anilino; morpholino).
There is therefore provided, as a further aspect of the invention, a method for the preparation of a compound of formula (I) comprising adapting or using any method known for the preparation of analogous compounds, and in particular those methods defined in (1) to
(2) hereinabove.
The compounds of the invention have been found to inhibit dihydrofolate reductase (DHFR) in mammals and other biological systems and to have antitumour activity; they also appear to have some antipsoriatic and antimalarial activity. Such antitumour activity is evidenced for example by reduction of tumour cell number in mammals bearing ascitic tumours and their consequent increase in survival as compared to a control group which is untreated. Antitumour activity is further evidenced by measurable reduction in the size of solid tumours following treatment with the compounds of this invention compared to the tumours of untreated control animals. The murine tumour lines against which the compounds of formula (I) are active include, but are not limited to, lymphocytic leukemia P388, lymphocytic leukemia L1210, melanotic melanoma B16 , Colon 38, TLX5 lymphoma, W3129 myeloma, Walker 256 and M5 recticulura cell sarcoma.
As has been described above, the compounds of the present invention are useful for the treatment of tumours. The invention thus further provides a method for the treatment of tumours in animals, including mammals, which comprises the administration of an effective, non-toxic amount of the compound of formula (I), or an acid addition salt thereof, orally, parenterally (including subcutaneous, intramuscular and intravenous), or applied topically. The administration will generally be carried out repetitively at intervals, for example once or several times a day. There is further provided as a further, or alternative, aspect of the invention, a compound of formula (I) or an acid addition salt thereof for use in therapy, for example as an antitumour agent. The amount of compounds of formula (I) required to be effective as an antitumour agent for treating mammals will, of course, vary and is ultimately at the discretion of the medical or veterinary practitioner treating the mammal in each particular case. The factors to be considered by such a practitioner, e.g. a physician, include the route of administration and pharmaceutical formulation; the mammal's body weight, surface area, age and general condition; and the particular salt or ester to be administered. However, a suitable effective antitumour dose is in the range of about 1.0 to about 75mg/kg bodyweight, preferably in the range of about 5 to 40mg/kg with most suitable doses being for example in the range 10 to 30mg/kg. In daily treatment for example, the total daily dose may be given as a single dose, multiple doses, e.g. two to six times per day, or by intravenous infusion for any selected duration. For example, for a 75kg mammal, the dose range would be about 75 to 500mg per day, and a typical dose would cqmraonly be about 100mg per day. If discrete multiple doses are indicated, treatment might typically be 50mg of a compound, of formula (I) given 4 times per day in the form of a tablet, capsule, liquid (e.g. syrup) or injection.
The antitumour activity of the compounds of formula (I) resides in the free base and thus the nature of the acid participating in the acid addition salts is of minor importance. However, when used in medicine, the salts of the compound of formula (I) should be both pharmacologically and pharmaceutically acceptable, but nonpharmaceutically and non-pharmacologically acceptable salts may conveniently be used to prepare the free active compound or pharmaceutically acceptable salts thereof and are not excluded from the scope of this Invention.
While it is possible for the active compound [defined herein as compound of formula (I)] to be administered alone as the raw chemical, it Is preferable to present the active compound as a pharmaceutical formulation. Formulations of the present invention, for medical use, comprise the active compound together with one or more pharmaceutically acceptable carriers thereof and, optionally, any other therapeutic ingredients. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof .
The present invention therefore further provides a pharmaceutical formulation comprising a compound of formula (I) (in the form of the free base or a pharmaceutically acceptable acid addition salt) together with a pharmaceutically acceptable carrier therefor.
The formulations include those suitable for oral, rectal or parenteral (including subcutaneous, intramuscular and intravenous) administration.
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include generally the step of bringing the active compound into association with a carrier which constitutes one or more accessory Ingredients. Usually, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier or with a finely divided solid carrier or with both and then, if necessary, shaping the product into desired formulations.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the active compound; as a powder or granules; or a suspension In an aqueous liquid or non-aqueous liquid such as a syrup, an elixir, an emulsion or a draught. The active compound may also be presented as a bolus, electuary or paste.
A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active compound in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, Inert diluent, surface active or dispersing agent. Moulded tablets may be made by moulding, In a suitable machine, a mixture of the powdered active compound with any suitable carrier.
A syrup may be made by adding the active compound to a concentrated, aqueous solution of a sugar, for example sucrose, to which may be added any accessory ingredient. Such accessory ingredient(s) may include flavourings, an agent to retard crystallisation of the sugar or an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol for example glycerol or sorbitol.
Formulations for rectal administration may be presented as a suppository with a usual carrier such as cocoa butter.
Formulations suitable for parental administration conveniently comprise a sterile aqueous preparation of the active compound which is preferably isotonic with the blood of the recipient.
In addition to the aforementioned Ingredients, the formulations of this Invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.
Overall, the invention comprises each and any novel feature or combination of features disclosed herein, but different aspects of the invention principally but not exclusively comprise broadly the following:-
(i) A compound of formula (I) as defined herein;
(ii) Processes for the preparation of compounds of formula (I) as defined herein; (iii) A pharmaceutical formulation comprising a compound of formula (I) as defined herein together with a pharmaceutically acceptable carrier therein; (iv) Processes for the preparation of a pharmaceutical formulation as defined in (iii) above by methods described herein; (v) Compounds of formula (I) for therapy or for use in medicine, for example as antitumour agents, antipsoriatic agents and antimalarial agents; (vi) A method for the therapy of a mammal having a malignant tumour comprising administration of a compound of formula (I).
DESCRIPTION OF EXAMPLES OF PREFERRED EMBODIMENTS
The following examples and descriptions of stages in synthetic routes of preparation of preferred compounds of formula (I) illustrate the invention but should not be construed in any way as a limitation thereof.
EXAMPLE 1 2,4-Diamino-5-(3-azido-4-chlorophenyl)-6-ethylpyrimidine - Compound (la)
Stages of Synthetic route of preparation
(i) 2,4-Diamino-5-(3-nitro-4-chlorophenyl)-6-ethylρyrimidine
To a stirred mixture of concentrated sulphuric acid (15 ml) and nitric acid (15 ml: D1.42) maintained below 15°C was added 2,4diamino-5-(4-chlorophenyl)-6-ethylpyrimidine ('pyrimethamine') (5g) over 1 hour. The mixture was heated to 50°C for 2 hours, cooled, poured onto ice (approx. 200g) and basified by the slow addition of concentrated aqueous ammonia. The cream nitropyrimidine (4.1g) was collected and crystallised from aqueous ethanol to afford bright yellow rosettes, m.p. 203-205°C; ν max 1340, 1560 (NO2), 1630, 3120, 3300 an add 3450 (NH ) cm-1; δ 1.00(3H,t,CH3), 2.15(2H,q,CH2), 5.93(2H,s,NH2), 6.03(2H,s,NH2), 7.51(lH,dd,6'-H), 7.81(2H,s,2'-H and 5'-H).
Found C, 49.3; H, 4.0; N, 23.6%
C12H12C11N5O2 requires C, 49.1; H, 4.1; N, 23.85%
This compound has been referred to twice in the literature but not characterised (J. Medicinal Chem. , 1969, 12, 662 and J. Chromatography, 1975, 106, 41).
(ii) 2, 4-Diamino-5-(3-amino-4-chlorophenyl)-6-ethylpyrimidine
2,4-diamino-5-(3-nitro-4-chlorophenyl)-6-ethylpyrimidine ( 16g) was added in small portions with stirring over 15 minutes to a solution of tin (II) chloride dihydrate (38g) in 10N-hydro- chloric acid (160ml) that was maintained at 5-10°C. The mixture was stirred thoroughly for 1.5 hours (using a mortar) and allowed to stand overnight. The white stannicomplex that was produced was collected, dissolved in hot water and basified to pH 14 with 10N sodium hydroxide. The resulting white precipitate was collected and crystallised from 100% ethanol to yield small amber prisms of the anhydrous base (9.5g), m.p 215-217°C; ν max 1622 br, 3180 br, 3320 and 3480 (NH2) cm-1; δ 1.00(3H,t,CH3), 2.18(2H,t,CH2), 5.35(2H,s,3'NH2), 5.69(2H,s,NH2), 5.90(2H,s,NH2), 6.65(lH,d, benzene 2'-H),
6.38 (1H,q, benzene 6'-H, J261.7Hz, J658Hz) 7.25(1H,d, benzene 5'-H).
Found: C, 54.4; H, 5.1; N, 26.4%
C12H14N5Cl requires C, 54.6; H, 5.3; N, 26.7%
This compound has been referred to (J. Medicinal Chem. 1969, 12, 662) but not characterised.
A sample of the crude white precipitate was also crystallised from 50% aqueous ethanol to afford colourless needles of the amine monohydrate, m.p. 215-217°C, m/e 265(31%), 263(96%; M+) , 247(100%);
1602, 3180 br, 3330, 3480 (NH9) cm-1. ν max
Found C, 50.0; H, 5.4; N, 24.9% C12H14N5C1,1¼H2O requires C, 50.4; H, 5.8; N, 24.5%
(iii) 2, 4-Diamino-5-( 3-azido-4-chlorophenyl)-6-ethy Ipyrimidine
A fine suspension of the 3-amino compound from (i) above (1.84g) in 5N-hydrochloride acid (60ml) was diazotised at 0°C by the addition of sodium nitrite (0.6g) dissolved in water (2ml), with stirring, over 15 min. When the resulting suspension had been stirred for 1 hour, sodium azide (1.8g) was added in small portions over 2 hours, the agitation being maintained.
Following basification to pH 9 with concentrated aqueous ammonia, and stirring for 0.5 hours, the solid product was collected (1.82g; 90%) and crystallised from ethanol to yield photosensitive cream microprisms of the azide base, m.p. 185-188°C(eff.); m/e 291(15%), 289(41%;M+),
263(21%), 262(39%), 226(66%), 65(100%); ν 1450, 1564 br, 1639 br, 2150 (N3), 3140 br, max
3300 and 3460 (NH.) cm ; δ 1.00(3H,t,CH3), 2.18(2H,q,CH2), 5.84(2H,s,NH2), 5.96(2H,s,NH2), 7.00(lH,q, benzene 6'-H, J622Hz, J658.4Hz), 7.19(lH,d, benzene 2'-H), 7.55( lH,d, benzene 5'-H).
Found: C, 49.9; H, 4.2; N, 33.3%
Cl2H12N7Cl requires C, 49.7; H, 4.2; N, 33.8% EXAMPLE 2 2, 4-Diamino-5-(3-azido-4-chloroρhenyl)-6-ethyIpyrimidine (la) salts
(I) The azide base (from Example 1) (1.0g) was dissolved in a minimal quantity of acetic acid (about 8ml). Following the addition of 10M-hydrochloric acid (2 ml) and standing for 48 hours ac 4°C in the dark, white microprisms of the azide monohydrochloride (0.5g), m.p.220-225°C, were deposited;
1542, 1575, 1600, 1642, 1660 infl., ν max
2180 (N3) cm -1 δ 1.08(3H,t,CH3), 2.30(q,CH2), 7.13(1H,q,6'-H), 7.39(1H,d,2'-H), 7.48(exchangeable,s), 7.68(1H,d,5'-H).
Found C, 44.3; H, 4.0; N, 30.3%
C12H12N7Cl,HCl requires C, 44.2; H, 4.0; N, 30.0%
(ii) Upon crystallisation in the dark of the azide base from acetic acid (8 days at 0°C) the azide diacetate was formed as colourless precipitate. This was dried at 100°C/750 torr for 3 hours to give a white powder, m.p. 190-195°C; ν 1320, 1542 infl., 1575, 1645, 1660 br, max
2180 (N3); no band 1700-1720 cm-1 (therefore acetic acid of crystallisation absent); & 1.02(3H,t,CH3), 1.93(1.5H,s,CH3COO), 2.20(q,CH2),
6.21(2H,br s,NH2), 6.50(2H,br s,NH2), 7.15 (H,q, benzene 6'-H), 7.22(lH,d,2'-H), 7.58 (1H,5'-H), 9.40 (br s,+NH).
Found: C, 46.5; H, 4.6% C12H14N7Cl,2C2H3O2 requires C, 46.9; H, 4.9%
(iii) The azide free base was treated with ethanesulphonic acid (1.1 mol. equiv.) to afford the azide ethanes ulp ho nate as a white precipitate. The azide ethanes ulpho nate was crystallised from water to give white crystals, m.p. 190-191°C (decomp); ν 2130 (N max 3) cm-1;
Found: C, 41.90; H, 4.3; N, 24.1%
C12H12C 1lN7.C2H6SO3 requires C, 42.05; H, 4.5; N, 24.5%
(iv) The azide free base (2.0g) was treated with raethanesulphonic acid (1.1 mol. equiv.) to afford the azide methanesulphonate salt (cream solid). The salt crystallised from water to give cream prisms, m.p. 201-202°C (decomp.) (0.9 g); v 2150 (N cm-1; max 3)
Found: C, 40.1; H, 4.3; N, 25.2% C12H12ClN7.CH3SO3H requires C, 40.2; H, 4.15; N, 25.4%
EXAMPLE 3 2, 4-Diamino-5-(3-azido-4-chloroρhenyl)-6-methy Ipyrimidine - Compound ( lb)
(i) 2, 4- Diamino-5-(3-amino-4-chlorophenyl)-6-me thy Ipyrimidine
To a suspension of 2,4-diamino-5-(3-nitro-4-chlorophenyl)-6- methylpyrimidine (10.0g) in ethanol (100ml) was added Raney nickel (10.0g) and the mixture was stirred at 60-65°C. Hydrazine hydrate (33 ml) was added dropwise over an hour with vigorous effervescence. The solution was filtered hot, through celite, and the ethanol was removed by vacuum evaporation. The cream solid (9.7g) crystallised from aqueous ethanol to afford microcrystals, m.p. 242-244°C.
(ii) 2 ,4-Diamino-5-(3-azido-4-chlorophenyl)-6-methy Ipyrimidine
A solution of the 2,4-diamino-5-(3-amino-4-chlorophenyl)-6methy Ipyrimidine (prepared above) (8.0g) in 5M-hydrochloric acid (130 ml) was stirred at 0°C and sodium nitrite (2.4g) dissolved in water (10 ml) was added over 30 minutes. Sodium azide (5.4g) was added in portions over one hour. After stirring for a further one hour concentrated aqueous ammonia was added (to pH 9.0) and the cream solid (95% yield) was collected.
The ethanesulphonate salt was prepared as follows: the azide (3.0g) was suspended in water (20ml) and ethanesulphonic acid (1.2g) was added. The mixture was heated to boiling and the solid dissolved. On cooling the salt crystallised out and was collected; it was then recrystallised from water to afford cream microcrystals (2.2g), m.p. 202-203°C (with decomposition); v 3350, 3175, 2900 (NH,) and max
2125 (N3) cm-1; δ 1.14(3H,t,CH3), 2.02(3H,s,CH3), 2.58(2H,q,CH2), 3.38(1H,s,NH), 7.06, 7.82, 8.18(4H, NH2), 7.17(1H,dd,6'-H), 7.45(1H,d,2'-H), 7.70(1H,d,5'-H).
Found: C, 40.0; H, 4.3; N, 25.2% C 1 1H10CIN7.C2H6SO3 requires C, 40.2 ; H, 4.15 ; N, 25 .4%
EXAMPLE 4 2 ,4-Diamino-5-(4-azido-3-chlorophenyl)-6-ethyIpyrimidine
- Compound ( le)
Synthetic route
( i) 2 ,4-Diamino-5-(3-chlorophenyl)-6-ethyIpyrimidine
α -Propionyl-3-chlorophenylacetonitrile ( 10g) was dissolved in ether (200ml) and diazomethane (4g) in ether (500ml) was added. After standing for 12 hours excess diazomethane was destroyed with acet ic acid. Removal of ether left an oil which was dissolved in ethanol (50ml) and a solution of guanidine (prepared from guanidine hydrochloride , 5 .8g) in ethanol (50ml) was added. The solution was refluxed for 4 hours and the chloropyrimidine (8.1g) was collected from the cooled solution, m.p. 211-213°C.
(ii) 2, 4-Diamino-5-(3-chloro-4-nitroplιenyl)-6-ethy Ipyrimidine
2, 4-diamino-5-(3-chlorophenyl)-6-ethy Ipyrimidine (19.0g) was added over 1 hour to a stirred mixture of nitric acid (60 ml, D 1.42) and sulphuric acid (60 ml) at 25°C. The yellow solution was stirred for a further 4 hours at 30°C and then quenched with water and basified with ammonia. The yellow nit ropy rimidine (23.0g) had a m.p. over 300°C (decomp).
Found: C, 49.3; H, 4.0; N, 23.6%
C.2H12ClN5O2 requires C, 49.1; H, 4.1; N, 23.85%
(iii) 2, 4-Diamino-5-(4-azido-3-chloroρhenyl)-6-ethy Ipyrimidine
2 ,4-diamino-5-(3-chloro-4-nitrophenyl)-6-ethylpyrimidine (16g) was reduced with a solution of tin (II) chloride dihydrate (38g) in ION-hydrochloric acid (160 ml) that was maintained at 5-10°C. The mixture was stirred overnight and the white stannicomplex collected. The stannicomplex was basified to pH 14 with ION- sodium hydroxide and the white residue of 2,4-diamino-5-(4- amino-3-chlorophenyl)-6-ethylpy rimidine was collected and washed with water. The crude aminopyrimidine (1.84g) was converted to 2, 4-diamino-5-(4-azido-3-chlorophenyl)-6-ethy Ipyrimidine by dissolving in 5N-hydrochloric acid (60 ml) at 0°C and treating the mixture, successively with sodium nitrite (0.6g) followed by sodium azide (1.8g) in the manner described for the synthesis of compound (la). The ethanesulphonate salt was prepared from the azide base and ethanesulphonic acid and crystallised from water as cream crystals, m.p. 196-197°C (decomp.) Found : C, 42.2; H, -4.4; N, 24.2%
C.2H12ClN7.C2H6SO3 requires C, 42.05; H, 4.5; N, 24.5%
EXAMPLE 5 2, 4-Diamino-5-(4-azido-3-chlorophenyl)-6-methyIpyrimidine
- Compound (If)
This azidopyrimidine was prepared from 2,4-diamino-5-(4-amino-3chlorophenyl)-6-methylpyrimidine (m.p. 242-244ºC) by the diazotisation and azidation procedure described in detail for the synthesis of compound (la). The ethanesulphonate salt was prepared from the azide base and ethanesulphonic acid in the manner described previously and crystallised from water as cream crystals, m.p. 202-203°C; ν max 2140 (N3) cm-1.
Found; C, 40.3; H, 4.4; N, 25.2% C11H10CLN7.C2H6SO3 requires C, 40.2; H, 4.15; N, 25.4%
EXAMPLE 6 2, 4-Diamino-5-(3-azido-4-methoxyphenyl)-6-ethyIpyrimidine
- Compound (Ic)
(I) 2 ,4-Diamino-5-(4-methoxy-3-nitrophenyl)-6-ethyIpyrimidine
To a solution of sodium metal (1.0g) in dry methanol (50 ml) was added 2,4-diamino-5-(4-chloro-3-nitrophenyl)-6-ethylpyrimidine (2.0g). The mixture was boiled (18 hours), cooled, and concentrated to 25 mis. Addition of water (50 ml) precipitated a yellow solid (1.9g) which crystallised from dimethylformamide as yellow crystals, m.p. 277-278°C (decomp.); & 0.90(3H,t,CH3), 2.10(2H,q,CH2), 3.75(3H,s,CH3), 7.1(1H,d,H'-2), 7.2(1H,dd,H'-6), 7.7(1H,d,H'-5).
Found C, 53.8; H, 4.9; N, 24.1%
C13H15N5O3 requires C, 54.0; H, 5.2; N, 24.22% (ii) 2,4-Diamino-5-(3-azido-4-methoxyphenyl)-6-ethyIpyrimidine
Reduction of 2,4-diamino-5-(4-methoxy-3-nitrophenyl)-6-ethylpyrimidine (10g) in ethanol (150mls) at 65°C with hydrazine hydrate (50 mLs) and Raney nickel catalyst gave a grey precipitate of crude 2 ,4-diamino-5-(3-amino-4-methoxyphenyl)-6ethyIpyrimidine (6.9g) when the catalyst was removed and the filtered solution was evaporated to dryness. The crude aminopyrimidine was used without further purification.
Synthesis of the azidopyrimidine was accomplished by diazotisation and azidation of 2,4-diamino-5-(3-amino-4-methoxyρhenyl)-6-ethyIpyrimidine in the manner described in detail for the synthesis of compound (la). The azide base was converted to the ethanesulphonate salt by treatment with ethanesulphonic acid in the manner already described and the salt was crystallised from water to furnish cream crystals, m.p. 272-274°C (decomp.); ν max 2130 (N3) cm-1;
Found C , 45 .8; H , 5.1 ; N, 24.6% C1 3H15N7O .C2H6SO3 requires C, 45.6 ; H, 5 .3 ; N, 24 .8%
EXAMPLE 7 2 , 4-Diamino-5-( 3-azido-4-ethoxyρhenyl)-6-ethylpyrimidine
- Compound ( Id)
This azidopyrimidine was likewise prepared from 2 ,4-diamino-5(3-amino-4-ethoxyphenyl)-6-ethylpyrimidine (m.p. 176-177 °C) by t reatment with sodium nitrite and sodium azide using the procedure used successfully for the synthesis of compound ( la ) . The azide base was converted to the ethanesulphonate salt by treatment with ethanesulphonic acid in the manner previous ly described . The cream salt crystallised from water as microcrystals , m.p. 173-174 °C ( decomp .) ; ν 2140 (N3) cm-1 max Found C, 47.1; H, 5.8; N, 23.8%
C14H17N7O.C2H6SO3 requires C, 46.95; H, 5.6; N, 24.0%
EXAMPLE 8 Activity of compounds of formula ( I) against dihydrofolate reductase
The inhibitory activity of 2 ,4-diamino-5-(3-azido-4-chlorophenyl)-6-ethylpyrimidine (compound la) against mouse lymphoma L1210 dihydrofolate reductase at various concentrations was determined and compared to that of pyrimethamine. The results are shown in Table I.
Compounds (Ia-If) were tested against dihydrofolate reductase obtained from rat. All the compounds tested had IC 50 concentrations , i.e. the concentrations required to inhibit the euzyme by 50%, of less than 10 -6 molar.
EXAMPLE 9 In vivo Antitumour Activity of Compound (la)
Methods for evaluating the antitumour activity of this compound are essentially those used In the Tumor Panel by the Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, A. Goldin, et al., Methods in Cancer Research, Vol. XVI, p.165, Academic Press (1979). (i) Lymphocytic Leukemia P388
CD2-F mice, of the same sex, weighing within a 3 gram range surrounding 20g, are used for this test. Control and test animals are injected intraperitoneally with a suspension of 106 viable P388/0 tumour cells on day 0. In each test several dose levels which bracket the LD 20 for the compound are evaluated; each dose level group contains 6 animals. The test compounds are prepared either in physiologic saline containing 0.05% Tween 80 or distilled water containing 5% dextrose and are administered intraperitoneally on days 1 to 9 relative to tumour implant. Doses are on a mg/kg basis according to individual animals' body weights. The day of death for each animal is recorded, the median identified for each group and the ratios of median survival time for treated (T)/control (C) groups are calculated. The criterion for activity is T/C x 100 120%. The results are summarised in Table II balow. No toxicity was observed with 9 daily doses of up to 200 mg/kg and increases in survival time of up to 57% were observed.
(ii) TLX5 Lymphoma
Five female CBA/LAC mice received an inoculum (s.c.) of 2 x
10 cells and were then treated with 5 daily i.p. injections of compound (la) in 10% DMSO/arachis oil starting on day 2. Survival time was determined and compared with controls receiving solvent only.
The results obtained are shown in Table (III) .
(iii) W3129 Myeloma
Groups of 5 female BALB/C mice were inoculated s.c. with 5 x
105 W3129 myeloma cells. A single dose of 100mg/kg of compound (la) in 25% DMSO/arachis oil was administered i.p. on day 2 and mean tumour diameter was determined on days 8, 10, 11 and 14 and compared to untreated controls. The results are shown in Table (IV).
a significantly untreated p 0.005 b significantly untreated p 0.01 d tumours having diameters 13mm were not accurately measurable

Claims

1. A compound comprising an azido-substituted pyrimidine derivative, or an acid addition salt thereof, having the general formula (I):
wherein the or each R1 is selected from hydrogen, halogen or alkoxy having a carbon chain of 1-4 carbon atoms, while R2 is hydrogen or an alkyl group of 1-4 carbon atoms.
2. A compound as claimed in Claim 1 wherein the azido group is in the 3'-position of the phenyl group, a said radical R1 consisting of a chlorine, bromine or iodine atom or an alkoxy group of 1-4 carbon atoms is in the 4'-position of the phenyl group, and the said radical R2 is an alkyl group of 1-4 carbon atoms.
3. A compound as claimed in Claim 2 wherein the formula is one of the following (la - Id):
H
or an acid addition salt thereof.
4. A compound as claimed in Claim 1 wherein the azido group is in the 4'-position of the phenyl group, a said radical R1 consisting of a chlorine, bromine or iodine atom or an alkoxy group of 1-4 carbon atoms is in the 3'-position of the phenyl group, and the said radical R2 is an alkyl group of 1-4 carbon atoms.
5. A compound as claimed in Claim 4 wherein the formula is one of the following (Ie - If):
or an acid addition salt thereof.
6. A compound as claimed in any one of Claims 1 to 5 further characterised in that It is an acid addition salt derived from an acid selected from the group comprising: hydrochloric, hydrobromic, sulphuric, nitric, isethionic, phosphoric, maleic, salicylic, ptoluenesulphonic, tartaric, citric, lactobionic, formic, malonlc, pantothenic, succinic, naphthalene-2-sulphonic, benzenesulphonic, methanesulphonic and ethanesulphonic.
7 . A process for preparing a compound as claimed in any one of
Claims 1 to 6 wherein the azido group is in the 3 ' - or 4 '-position of the phenyl group, characterised in that it includes the step of diazotisation of the corresponding amino corαpound of formula ( II) :
wherein R1 and R2 are as hereinbefore defined in Claim 1, followed by the step of treatment with azide.
8. A process as claimed in Claim 7 wherein the compound of formula II is first prepared by reduction of the corresponding nitro compound.
9. A process for preparing a compound as claimed in any one of Claims 1 to 6 wherein the azido group is in the 3'- or 4'-position of the phenyl group, characterised in that it includes the step of reacting with guanidine a compound of formula (III):
wherein R1 and R2 are as hereinbefore defined in Claim 1 , and Y is a residue or group selected from alkoxy, aralkoxy, alkylthio, aralkylthio, dialkylamino, anilino and morpholino.
10. A compound as claimed in any one of Claims 1 to 6 for therapeutic use as an antitumour, antipsoviatic or antimalarial agent in treating mammals.
11. A compound as claimed in Claim 10 in the form of a pharmacologically and pharmaceutically acceptable acid addition salt.
12. A compound as claimed in Claim 10 or 11 in unit dosage form made up for administration to the mammal.
13. A compound as claimed in Claim 10 or 11 in combination with a pharmaceutically acceptable carrier or vehicle.
14. A pharmaceutical formulation for medical use comprising, as the active compound, a compound as claimed in any one of Claims 1 to 6 in the form of the free base or a pharmaceutically acceptable acid addition salt together with a pharmaceutically acceptable carrier therefor.
15. A method of preparing a pharmaceutical formulation as specif ied in Claim 14, said method comprising the step of bringing the said act ive compound into associat ion with said carrier which const itutes one or more accessory ingredients.
16. An azido-substituted pyrimidine derivat ive having the general formula ( I) :
wherein R1 is a chlorine, bromine or iodine atom or an alkoxy group of 1-4 carbon atoms in the 4'- or 3 '-position of the phenyl group, the azido group (N3) is in the 3'- or 4'-position of the phenyl group, and R2 is an alkyl group of 1-4 carbon atoms, provided in the form of the free base or an acid addition salt thereof, for use as an active therapeutic substance.
17. A medical preparation containing an azido-substituted pyrimidine derivative having the general formula (I) as claimed in Claim 16, or an acid addition salt thereof, and a pharmaceutical excipient.
18. 2,4-Diamino-5-(3-azido-4-chlorophenyl)-6-ethyIpyrimidine, or an acid addition salt thereof, for use as an active therapeutic substance.
19. 2,4-Diamino-5-(3-azido-4-chlorophenyl)-6-methyIpyrimidine, or an acid addition salt thereof, for use as an active therapeutic substance.
20. 2,4-Diamino-5-(3-azido-4-methoxyphenyl)-6-ethyIpyrimidine, or an acid addition salt thereof, for use as an active therapeutic substance.
21. 2,4-Diamino-5-(3-azido-4-ethoxyphenyl)-6-ethyIpyrimidine, or an acid addition salt thereof, for use as an active therapeutic substance.
22. 2,4-Diamino-5-(4-azido-3-chlorophenyl)-6-ethyIpyrimidine, or an acid addition salt thereof, for use as an active therapeutic substance.
23. 2,4-Diamino-5-(4-azido-3-chlorophenyl)-6-methyIpyrimidine, or an acid addition salt thereof, for use as an active therapeutic substance.
24. A medical preparation containing an azido-substituted 2 , 4diamino-5-pheny Ipyrimidine as claimed in any one of Claims 18 to 23 , or an acid addition salt thereof , and a pharmaceutical excipient .
25. Use in antitumour, antipsoriatic or antimalarial therapy of the free base form, or an acid addition salt , of an azido-substituted pyrimidine derivative having the general formula ( I) :
wherein R 1 is a chlorine, bromine or iodine atom or an alkoxy group of 1-4 carbon atoms in the 4 '- or 3 '-posit ion of the phenyl group, the azido group (N3) is in the 3 '- or 4 '-position of the phenyl group, and R2 is an alkyl group of 1-4 carbon atoms.
EP19840902351 1983-05-26 1984-05-29 Pyrimidine derivatives Ceased EP0147443A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8314643 1983-05-26
GB838314643A GB8314643D0 (en) 1983-05-26 1983-05-26 Pyrimidine derivatives

Publications (1)

Publication Number Publication Date
EP0147443A1 true EP0147443A1 (en) 1985-07-10

Family

ID=10543429

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19840902351 Ceased EP0147443A1 (en) 1983-05-26 1984-05-29 Pyrimidine derivatives

Country Status (5)

Country Link
EP (1) EP0147443A1 (en)
JP (1) JPS60502255A (en)
AU (1) AU3016884A (en)
GB (2) GB8314643D0 (en)
WO (1) WO1984004746A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE90673T1 (en) * 1986-12-02 1993-07-15 British Tech Group ANTIFOLATE AGENT.
GB9214994D0 (en) * 1992-07-15 1992-08-26 Shea Dennis M O Pyrimidine compounds
GB9700664D0 (en) * 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
CN1083040C (en) * 1997-08-11 2002-04-17 东芝株式会社 Method of building factory of shared image information and checkout method during service life
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
PL424999A1 (en) * 2018-03-22 2019-09-23 Glg Pharma Spółka Akcyjna Pharmaceutically acceptable 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1032239A (en) * 1950-02-15 1953-06-30 Wellcome Found Pyrimidine derivatives and their preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8404746A1 *

Also Published As

Publication number Publication date
JPS60502255A (en) 1985-12-26
AU3016884A (en) 1984-12-18
GB8501742D0 (en) 1985-02-27
GB2152508B (en) 1986-10-15
GB8314643D0 (en) 1983-06-29
GB2152508A (en) 1985-08-07
WO1984004746A1 (en) 1984-12-06

Similar Documents

Publication Publication Date Title
JPH07228558A (en) Stilbene derivative and carcinostatic agent containing the same
CS265248B2 (en) Process for preparing analogs of rebeccamycine
JPH0725785B2 (en) Adenosine derivative and pharmaceutical composition containing the compound as an active ingredient
PL192864B1 (en) Pyrazine compounds
EP4038063B1 (en) Heterocyclic compounds for inhibiting tyk2 activities
Krapcho et al. Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1, 4-bis [(aminoalkyl) amino] anthracene-9, 10-diones and 1, 4-bis [(aminoalkyl) amino]-5, 8-dihydroxyanthracene-9, 10-diones
US4826850A (en) Quinoline base compound, process for the preparation thereof and anticancer agent containing the same as pharmacologically efficacious component
EP0147443A1 (en) Pyrimidine derivatives
EP0290558B1 (en) Antifolate agents
HU217551B (en) 6 [(2-Hydroxyethyl) aminoalkyl] -5,11-dioxo-5,6-dihydro-11H-indene [1,2-c] isoquinoline derivatives, as well as a process for their preparation, and as an active ingredient therein. pharmaceutical preparations
JPS6344577A (en) Pyrimidine derivative
HU204536B (en) Process for producing new s-adenozyl-methionine decarboxylase- inhibitors
EP3907221A1 (en) Fluorine-containing substituted benzothiophene compound, and pharmaceutical composition and application thereof
RU2114839C1 (en) 2,3,4,5-tetrahydro-1h-3-benzazepines, pharmaceutical composition, method of treatment and methods of synthesis
EP0378706B1 (en) 5-substituted uridine derivatives and intermediates for their preparation
WO2016127949A1 (en) Pyrimidine derivative as inhibitor for t790 mutation
AU678975B2 (en) Pyrimidine compounds used in the therapy
JPH06211762A (en) N-methyldeacetylcolchiceinamide derivative
EP0186454B1 (en) 6-purinyl n-(2-chloroethyl) carbamate and thiocarbamate, a process for their preparation and use thereof
US4820706A (en) Pteridine derivatives and method of treating leukemia employing same
EP0154173B1 (en) Pteridine derivatives, an anticancer composition containing same and a process for the production of said derivatives
US6458983B1 (en) Method for synthesizing complexes of platinum with iminoethers and their use as antitumoral drugs and nucleotide-base modifiers
KR100751847B1 (en) Synthesis and Characterization of Novel Antiphorates, Puro [2,3-d] pyrimidine Derivatives
JPH0251422B2 (en)
US3749782A (en) Uracil ureas for reviving an animal given an overdose of barbiturate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

17P Request for examination filed

Effective date: 19850603

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BLISS, EDWARD, A.

Inventor name: STEVENS, MALCOLM, FRANCIS, GRAHAM

Inventor name: GRIFFIN, ROGER, JOHN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE WELCOME FOUNDATION LIMITED

Owner name: ASTON MOLECULES LIMITED

17Q First examination report despatched

Effective date: 19870701

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19880731

RIN1 Information on inventor provided before grant (corrected)

Inventor name: STEVENS, MALCOLM, FRANCIS, GRAHAM

Inventor name: GRIFFIN, ROGER, JOHN

Inventor name: BLISS, EDWARD, A.